Gold prices steady amid Fed rate cut hopes; Trump-Putin talks awaited
ANN ARBOR, Mich. - Esperion Therapeutics (NASDAQ:ESPR) has entered into an exclusive license and distribution agreement with CSL (OTC:CSLLY) Seqirus for the commercialization of its cholesterol-lowering drugs NEXLETOL® and NEXLIZET® in Australia and New Zealand, the company announced Monday. CSL Limited (ASX:CSL), the parent company of CSL Seqirus, is currently trading near its 52-week low but shows strong fundamentals according to InvestingPro data, with a perfect Piotroski Score of 9 and a market capitalization of $15.15 billion.
Under the terms of the agreement, Esperion will receive an upfront payment and is eligible for milestone payments that could total approximately $5 million. The company will also supply CSL Seqirus with the finished products at a profitable transfer price. CSL brings strong financial backing to this partnership, with InvestingPro analysis showing robust revenue growth of 9.08% and healthy profit margins. Get access to 15+ additional ProTips and comprehensive financial metrics with an InvestingPro subscription.
Cardiovascular disease is a major health concern in both countries, affecting millions and leading to a high number of deaths annually. This partnership aims to address this issue by providing additional treatment options for high LDL-C cholesterol, which is linked to cardiovascular risk.
"We are excited to partner with CSL Seqirus to provide physicians and patients with additional options to treat high LDL-C cholesterol and reduce the risk of cardiovascular disease in Australia and New Zealand," said Sheldon Koenig, President and CEO of Esperion.
CSL Seqirus, a subsidiary of CSL Limited (ASX:CSL), will be responsible for the commercialization of the drugs, which includes obtaining regulatory approvals, reimbursement, and marketing in the respective countries.
NEXLETOL® and NEXLIZET® are indicated for adults with established cardiovascular disease or those at high risk, particularly when statin therapy is not possible or sufficient. The drugs work as an adjunct to diet, alone or in combination with other LDL-C lowering therapies.
The announcement highlighted the safety profile of the drugs, noting contraindications in patients with hypersensitivity to their components and the potential for serious adverse reactions such as hyperuricemia, tendon rupture, and others.
This agreement marks an expansion of Esperion’s global reach, aiming to provide potentially lifesaving medications to a larger market. CSL’s strong financial position, with a current ratio of 2.89 and manageable debt levels, suggests it’s well-positioned to execute this expansion. For detailed insights into CSL’s valuation and growth potential, including exclusive Fair Value analysis and expert projections, check out the comprehensive Pro Research Report available on InvestingPro.
The information in this article is based on a press release statement from Esperion Therapeutics.
In other recent news, Carlisle Companies (NYSE:CSL) Incorporated reported its fourth-quarter 2024 earnings, revealing an adjusted earnings per share (EPS) of $4.47, which exceeded the forecast of $4.42. However, the company’s revenue for the quarter was $1.1 billion, falling short of the expected $1.16 billion. Despite the revenue miss, Carlisle achieved a record adjusted EPS of $20.2 for the full year, marking a 30% increase year-over-year. The company’s strategic initiatives, including a pivot to a pure-play building products company, contributed to this growth. Looking ahead, Carlisle anticipates mid-single-digit consolidated revenue growth in 2025 and aims for double-digit EPS growth. The company also plans to execute $800 million in share buybacks and focus on bolt-on acquisitions. Analyst firms have noted the company’s strategic direction and performance, with some expressing concerns over potential pricing pressures in early 2025. Despite these challenges, Carlisle’s leadership remains optimistic about future prospects, driven by innovation and operational efficiencies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.